Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

AP Kater; S Kersting; Yvette van Norden; J Dubois; JA Dobber; CH Mellink; LM Evers; F Boer; J Schreurs; E van der Spek; H Visser; C Idink; S Wittebol; M Hoogendoorn; SH Tonino; M Mobasher; M-D Levin

doi:10.1182/bloodadvances.2018019422

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

AP Kater
, S Kersting
, Yvette van Norden
, J Dubois
, JA Dobber
, CH Mellink
, LM Evers
, F Boer
, J Schreurs
, E van der Spek
, H Visser
, C Idink
, S Wittebol
, M Hoogendoorn
, SH Tonino
, M Mobasher
, M-D Levin

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

25 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	3566-3571
Number of pages	6
Journal	Blood advances
Volume	2
Issue number	24
DOIs	https://doi.org/10.1182/bloodadvances.2018019422
Publication status	Published - 2018

Research programs

EMC OR-01

Access to Document

10.1182/bloodadvances.2018019422

Cite this

Kater, AP., Kersting, S., van Norden, Y., Dubois, J., Dobber, JA., Mellink, CH., Evers, LM., Boer, F., Schreurs, J., van der Spek, E., Visser, H., Idink, C., Wittebol, S., Hoogendoorn, M., Tonino, SH., Mobasher, M., & Levin, M.-D. (2018). Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood advances, 2(24), 3566-3571. https://doi.org/10.1182/bloodadvances.2018019422

@article{41e448d72aee49abb7ecbd1e5d047ade,

title = "Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL",

author = "AP Kater and S Kersting and \{van Norden\}, Yvette and J Dubois and JA Dobber and CH Mellink and LM Evers and F Boer and J Schreurs and \{van der Spek\}, E and H Visser and C Idink and S Wittebol and M Hoogendoorn and SH Tonino and M Mobasher and M-D Levin",

year = "2018",

doi = "10.1182/bloodadvances.2018019422",

language = "Undefined/Unknown",

volume = "2",

pages = "3566--3571",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "24",

}

Kater, AP, Kersting, S, van Norden, Y, Dubois, J, Dobber, JA, Mellink, CH, Evers, LM, Boer, F, Schreurs, J, van der Spek, E, Visser, H, Idink, C, Wittebol, S, Hoogendoorn, M, Tonino, SH, Mobasher, M & Levin, M-D 2018, 'Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL', Blood advances, vol. 2, no. 24, pp. 3566-3571. https://doi.org/10.1182/bloodadvances.2018019422

TY - JOUR

T1 - Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

AU - Kater, AP

AU - Kersting, S

AU - van Norden, Yvette

AU - Dubois, J

AU - Dobber, JA

AU - Mellink, CH

AU - Evers, LM

AU - Boer, F

AU - Schreurs, J

AU - van der Spek, E

AU - Visser, H

AU - Idink, C

AU - Wittebol, S

AU - Hoogendoorn, M

AU - Tonino, SH

AU - Mobasher, M

AU - Levin, M-D

PY - 2018

Y1 - 2018

U2 - 10.1182/bloodadvances.2018019422

DO - 10.1182/bloodadvances.2018019422

M3 - Article

C2 - 30552161

SN - 2473-9529

VL - 2

SP - 3566

EP - 3571

JO - Blood advances

JF - Blood advances

IS - 24

ER -